Financial Report Card - Report on Aethlon Medical

NEW YORK, September 16, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Aethlon Medical, Inc. (NASDAQ: AEMD). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/reports?keyword=AEMD

Highlights from our AEMD Report include:

• Q1 FY 2016 Results at a Glance- In a press release dated August 13, 2015, Aethlon Medical, Inc. reported results for the first quarter of fiscal 2016 (period ended June 30, 2015). The Company recorded revenues of $192,508 from government contracts during the quarter, which indicated over threefold growth over revenues of $51,296 generated in the first quarter of fiscal 2015. The Company has attributed this increase in revenue to a milestone achievement under DARPA contract in the 2016 period. Net loss attributable to common stockholders came in at $1.2 million or $0.18 loss per share in Q1 FY 2016, compared to net loss of $3.7 million or $0.80 loss per share for Q1 FY 2015.

• Operational Performance Review - The Company reported consolidated operating expenses of $1.3 million compared to $1.2 million in the corresponding quarter prior year. Professional fees were $538,226 during the quarter as compared to $401,613 in the prior year quarter. The Company has attributed this $136 thousand increase in professional fees to an increase in non-DARPA-related professional fees of $237 thousand. Payroll and related expenses came at $458,228, lower from $620,686 in the first quarter of last year, impacted by a $120 thousand decrease in stock-based compensation due to vesting of stock option grants issued in July 2013 and June 2014 and to a $42 thousand reduction in cash-based compensation due to headcount reductions from the 2014 period. The Company's General and administrative expenses were $286,025 during Q1 FY 2016, higher from $201,005 in the first quarter of last year, primarily due to an increase of $110 thousand in non-DARPA-related general and administrative expenses. The Company reported an operating loss of $1.1 million during Q2 FY 2016, as compared to an operating loss of $1.2 million during Q2 FY 2015.

• Management Opinion - Providing a glimpse about key corporate actions and future business outlook, Jim Joyce, Chairman and CEO of Aethlon Medical, stated, "We continued to strengthen our balance sheet through the completion of a $6 million equity financing and our shares began trading on Nasdaq, which broadens our access to the capital markets. As a result of the financing, we have the capital resources to support the FDA-approved study we initiated to advance Hemopurifier® therapy as a candidate to treat a broad-spectrum of viral pathogens. Additionally, we are better positioned to pursue clinical opportunities that exist for our Hemopurifier® in cancer care."

To find out how this influences our rating on Aethlon Medical, Inc., read the full report in its entirety here: http://www.aciassociation.com/reports?keyword=AEMD

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.  

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com